HSBC Downgrades Eli Lilly, Shares Drop 6%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: CNBC
- Market Expectation Downgrade: HSBC analysts project the GLP-1 obesity market to be between $80 billion and $120 billion by 2032, significantly lower than the consensus of over $150 billion, indicating that market optimism regarding Eli Lilly's future growth may be overly optimistic.
- Intensified Price Competition: Analysts argue that price competition in the GLP-1 market is likely to be significant, although Lilly's 2026 guidance suggests the company will achieve enough volume growth to offset pricing pressures from its agreement with the Trump administration, which could impact profitability.
- Cash-Pay Dependency Risk: Eli Lilly's reliance on the cash-pay market could become problematic if the U.S. economy slows down, particularly as middle-class consumers may have less disposable income to spend on GLP-1 drugs, potentially limiting sales and affecting company performance.
- Compliance Concerns: HSBC expresses concerns about the long-term performance of Lilly's upcoming obesity pill, suggesting that the market's assumptions about patient adherence are inconsistent with discontinuation rates observed in clinical trials, which may increase investment risk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 989.120
Low
950.00
Averages
1192
High
1500
Current: 989.120
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Growth Accelerates Amid High Valuation Concerns
- GLP-1 Drug Growth: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, significantly boosting revenue and expected to maintain strong growth, solidifying its leadership in the global healthcare market.
- Valuation Pressure: With a market cap around $900 billion and trading at over 40 times trailing earnings, Eli Lilly's high valuation may hinder investors' ability to achieve strong returns in the future, necessitating careful risk assessment.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could add a fast-growing product to its portfolio, enhancing market competitiveness and attracting more investor interest.
- Increasing Competition: While Eli Lilly currently dominates the GLP-1 space, it may face increased competition in the future, with other healthcare companies potentially eroding its market share, making investments at such high valuations risky.
See More
Analyst Downgrades Lilly, Market Expectations for Obesity Drugs Too High
- Elevated Market Expectations: Analysts believe that expectations for the total addressable market for obesity drugs exceed $150 billion, while projections suggest it may only reach $80 billion to $120 billion by 2032, indicating overly optimistic market sentiments that could negatively impact Lilly's stock performance.
- Rating Downgrade Impact: HSBC analyst Rajesh Kumar downgraded Lilly's rating from 'Hold' to 'Reduce' and lowered the price target from $1,070 to $850, suggesting a potential downside of about 14%, which could undermine investor confidence.
- Drug Approval Progress: Lilly's oral obesity pill orforglipron is currently under FDA review, with a decision expected in April; however, analysts caution that expectations for its launch may be too high, as compliance and persistence with the drug could disappoint.
- Intensifying Competition: Lilly's oral drug only led to a 12.4% weight loss in clinical trials, compared to Novo Nordisk's Wegovy, which achieved a 16.6% reduction, highlighting Lilly's competitive disadvantages that may affect its market share.
See More
HSBC Downgrades Eli Lilly, Shares Drop 6%
- Market Expectation Downgrade: HSBC analysts project the GLP-1 obesity market to be between $80 billion and $120 billion by 2032, significantly lower than the consensus of over $150 billion, indicating that market optimism regarding Eli Lilly's future growth may be overly optimistic.
- Intensified Price Competition: Analysts argue that price competition in the GLP-1 market is likely to be significant, although Lilly's 2026 guidance suggests the company will achieve enough volume growth to offset pricing pressures from its agreement with the Trump administration, which could impact profitability.
- Cash-Pay Dependency Risk: Eli Lilly's reliance on the cash-pay market could become problematic if the U.S. economy slows down, particularly as middle-class consumers may have less disposable income to spend on GLP-1 drugs, potentially limiting sales and affecting company performance.
- Compliance Concerns: HSBC expresses concerns about the long-term performance of Lilly's upcoming obesity pill, suggesting that the market's assumptions about patient adherence are inconsistent with discontinuation rates observed in clinical trials, which may increase investment risk.
See More
HSBC Downgrades Eli Lilly Stock to Sell
- Rating Downgrade: HSBC's downgrade of Eli Lilly's stock to 'sell' resulted in a 5% drop in share price by noon on Tuesday, reflecting market concerns about the company's future growth prospects.
- Pessimistic Market Outlook: While most analysts forecast a total addressable market exceeding $150 billion for obesity drugs, HSBC's analyst predicts annual revenues for GLP-1 weight-loss drugs will only reach $80 billion to $120 billion by 2032, indicating a bearish outlook.
- Intensifying Price Competition: The decline in GLP-1 drug prices suggests significant future price competition, with multiple rounds of price cuts already observed in 2025 and 2026, which could adversely affect revenue.
- Increased Valuation Risks: With a current P/E ratio of 43 times and earnings growth expectations of only 22% or less over the next five years, if HSBC's predictions hold true, Eli Lilly's stock may be overvalued, prompting caution among investors.
See More
US Stocks Rise Amid Oil Price Surge and Economic Data
- Market Performance: The S&P 500 Index rose by 0.64%, the Dow Jones Industrial Average increased by 0.59%, and the Nasdaq 100 Index climbed by 0.80%, indicating strong support from chipmakers and travel stocks, reflecting investor confidence in economic recovery.
- Employment Data Impact: The ADP report revealed an increase of only 9,000 jobs in February, the smallest gain in five weeks, signaling a slowdown in hiring by US employers, which contributed to a 2 basis point drop in the 10-year T-note yield to 4.20%, providing support for stocks.
- Oil Price Volatility: WTI crude oil prices surged over 1% due to Iranian attacks on key energy infrastructure in the Middle East, with the IEA warning that the conflict could disrupt global oil supply by 8 million barrels per day, further driving up prices.
- Fed Policy Expectations: The market widely anticipates that the Federal Reserve will keep interest rates unchanged at the upcoming FOMC meeting, despite the core PCE price index exceeding target levels, indicating persistent inflation pressures that may influence future monetary policy.
See More
Market Highlights: Tech and Entertainment Stocks Shine
- Executive Buy Signal: Builders FirstSource's director Paul Levy disclosed a purchase of 50,000 shares at $87.73 each in a regulatory filing, totaling $4.4 million, indicating strong confidence in the company's future growth and potentially attracting more investor interest.
- Dividend Increase and Buyback Plan: Qualcomm announced an increase in its quarterly cash dividend from 89 cents to 92 cents per share and approved a $20 billion stock repurchase authorization, which is expected to enhance shareholder returns and boost market confidence.
- Acquisition Proposal Competition: Victory Capital submitted a revised proposal to acquire Janus Henderson Group, raising its cash offer to $40 per share and including a fixed exchange ratio of 0.25 shares of Victory stock, reflecting strong interest in consolidation within the asset management industry.
- Optimistic Airline Outlook: Despite rising fuel prices, Delta Air Lines and American Airlines both issued positive revenue forecasts, with Delta expecting revenue growth to exceed initial expectations and American projecting total revenue to rise over 10%, indicating a robust recovery in air travel demand.
See More
Eli Lilly's Growth Accelerates Amid High Valuation Concerns
- GLP-1 Drug Growth: Eli Lilly's GLP-1 treatments, Zepbound and Mounjaro, are in high demand, significantly boosting revenue and expected to maintain strong growth, solidifying its leadership in the global healthcare market.
- Valuation Pressure: With a market cap around $900 billion and trading at over 40 times trailing earnings, Eli Lilly's high valuation may hinder investors' ability to achieve strong returns in the future, necessitating careful risk assessment.
- New Product Launch: The company plans to launch a GLP-1 weight loss pill this year, which could add a fast-growing product to its portfolio, enhancing market competitiveness and attracting more investor interest.
- Increasing Competition: While Eli Lilly currently dominates the GLP-1 space, it may face increased competition in the future, with other healthcare companies potentially eroding its market share, making investments at such high valuations risky.
See More
Analyst Downgrades Lilly, Market Expectations for Obesity Drugs Too High
- Elevated Market Expectations: Analysts believe that expectations for the total addressable market for obesity drugs exceed $150 billion, while projections suggest it may only reach $80 billion to $120 billion by 2032, indicating overly optimistic market sentiments that could negatively impact Lilly's stock performance.
- Rating Downgrade Impact: HSBC analyst Rajesh Kumar downgraded Lilly's rating from 'Hold' to 'Reduce' and lowered the price target from $1,070 to $850, suggesting a potential downside of about 14%, which could undermine investor confidence.
- Drug Approval Progress: Lilly's oral obesity pill orforglipron is currently under FDA review, with a decision expected in April; however, analysts caution that expectations for its launch may be too high, as compliance and persistence with the drug could disappoint.
- Intensifying Competition: Lilly's oral drug only led to a 12.4% weight loss in clinical trials, compared to Novo Nordisk's Wegovy, which achieved a 16.6% reduction, highlighting Lilly's competitive disadvantages that may affect its market share.
See More
HSBC Downgrades Eli Lilly, Shares Drop 6%
- Market Expectation Downgrade: HSBC analysts project the GLP-1 obesity market to be between $80 billion and $120 billion by 2032, significantly lower than the consensus of over $150 billion, indicating that market optimism regarding Eli Lilly's future growth may be overly optimistic.
- Intensified Price Competition: Analysts argue that price competition in the GLP-1 market is likely to be significant, although Lilly's 2026 guidance suggests the company will achieve enough volume growth to offset pricing pressures from its agreement with the Trump administration, which could impact profitability.
- Cash-Pay Dependency Risk: Eli Lilly's reliance on the cash-pay market could become problematic if the U.S. economy slows down, particularly as middle-class consumers may have less disposable income to spend on GLP-1 drugs, potentially limiting sales and affecting company performance.
- Compliance Concerns: HSBC expresses concerns about the long-term performance of Lilly's upcoming obesity pill, suggesting that the market's assumptions about patient adherence are inconsistent with discontinuation rates observed in clinical trials, which may increase investment risk.
See More
HSBC Downgrades Eli Lilly Stock to Sell
- Rating Downgrade: HSBC's downgrade of Eli Lilly's stock to 'sell' resulted in a 5% drop in share price by noon on Tuesday, reflecting market concerns about the company's future growth prospects.
- Pessimistic Market Outlook: While most analysts forecast a total addressable market exceeding $150 billion for obesity drugs, HSBC's analyst predicts annual revenues for GLP-1 weight-loss drugs will only reach $80 billion to $120 billion by 2032, indicating a bearish outlook.
- Intensifying Price Competition: The decline in GLP-1 drug prices suggests significant future price competition, with multiple rounds of price cuts already observed in 2025 and 2026, which could adversely affect revenue.
- Increased Valuation Risks: With a current P/E ratio of 43 times and earnings growth expectations of only 22% or less over the next five years, if HSBC's predictions hold true, Eli Lilly's stock may be overvalued, prompting caution among investors.
See More
US Stocks Rise Amid Oil Price Surge and Economic Data
- Market Performance: The S&P 500 Index rose by 0.64%, the Dow Jones Industrial Average increased by 0.59%, and the Nasdaq 100 Index climbed by 0.80%, indicating strong support from chipmakers and travel stocks, reflecting investor confidence in economic recovery.
- Employment Data Impact: The ADP report revealed an increase of only 9,000 jobs in February, the smallest gain in five weeks, signaling a slowdown in hiring by US employers, which contributed to a 2 basis point drop in the 10-year T-note yield to 4.20%, providing support for stocks.
- Oil Price Volatility: WTI crude oil prices surged over 1% due to Iranian attacks on key energy infrastructure in the Middle East, with the IEA warning that the conflict could disrupt global oil supply by 8 million barrels per day, further driving up prices.
- Fed Policy Expectations: The market widely anticipates that the Federal Reserve will keep interest rates unchanged at the upcoming FOMC meeting, despite the core PCE price index exceeding target levels, indicating persistent inflation pressures that may influence future monetary policy.
See More
Market Highlights: Tech and Entertainment Stocks Shine
- Executive Buy Signal: Builders FirstSource's director Paul Levy disclosed a purchase of 50,000 shares at $87.73 each in a regulatory filing, totaling $4.4 million, indicating strong confidence in the company's future growth and potentially attracting more investor interest.
- Dividend Increase and Buyback Plan: Qualcomm announced an increase in its quarterly cash dividend from 89 cents to 92 cents per share and approved a $20 billion stock repurchase authorization, which is expected to enhance shareholder returns and boost market confidence.
- Acquisition Proposal Competition: Victory Capital submitted a revised proposal to acquire Janus Henderson Group, raising its cash offer to $40 per share and including a fixed exchange ratio of 0.25 shares of Victory stock, reflecting strong interest in consolidation within the asset management industry.
- Optimistic Airline Outlook: Despite rising fuel prices, Delta Air Lines and American Airlines both issued positive revenue forecasts, with Delta expecting revenue growth to exceed initial expectations and American projecting total revenue to rise over 10%, indicating a robust recovery in air travel demand.
See More
